KDR and renal cell carcinoma: Sunitinib is approved for the treatment of RCC in adjuvant and advanced settings, though its clinical utilization has decreased as newer VEGFR-TKIs have become available and immunotherapy doublets have shown better efficacy over sunitinib in controlled cohorts.